Why Am I Not Immune to Hep B After Vaccination?

Somewhere between 5 and 10 percent of healthy adults who complete the standard three-dose hepatitis B vaccine series never develop enough antibodies to be considered protected. These people are classified as “non-responders,” defined by an antibody level below 10 IU/L on blood testing. The reasons range from genetics to body composition to the way the shot was given, and in many cases a second round of vaccination solves the problem. But the first thing worth sorting out is whether you truly failed to respond or whether your antibodies simply faded over time, because those are very different situations.

Waning Antibodies Are Not the Same as Non-Response

If you were vaccinated as a child and a blood test years later shows antibody levels below the protective threshold, that does not necessarily mean the vaccine failed. Antibody levels naturally decline over time, sometimes to undetectable levels, while the immune memory that matters for real-world protection can persist for decades. A study following Thai adults vaccinated as infants found that 20 years later, over 93 percent still mounted a strong immune response when given a single challenge dose of the vaccine, even though many had low or undetectable antibodies beforehand.

A separate study in adults vaccinated during adulthood found that even among the roughly 10 percent whose antibodies had dropped below protective levels 20 to 30 years after their primary series, every single participant mounted an immune memory response within 30 days of a booster dose.

Research in children and adolescents tells the same story: despite waning antibody numbers, nearly all subjects retained the ability to respond rapidly when re-exposed to the vaccine antigen.

So if your doctor tells you your hepatitis B antibodies are low many years after vaccination, the most likely explanation in a healthy person is that your immune memory is still intact but your circulating antibodies have faded. A single booster dose usually proves this. True non-response, where the immune system never learned to recognize the virus at all, is a distinct problem with different causes.

Your Genes Play a Major Role

The single biggest factor behind genuine vaccine non-response is genetic. Your immune system uses a set of proteins called HLA molecules to present bits of foreign material to your immune cells. Certain HLA variants are less effective at presenting the hepatitis B surface antigen, which means some people’s immune systems essentially never get a clear look at what the vaccine is showing them.

Research has linked several specific HLA gene variants to poor vaccine response. An early study of hemodialysis patients found that the HLA-A1, B8, DR3 combination was far more common in non-responders than in people who responded well.

⁴

More recent work has expanded the picture considerably. A scoping review identified at least ten different HLA-II alleles involved in non-response, with certain variants like DRB1*07 consistently linked to vaccine failure across populations in the United States and Belgium, while variants like DRB1*01 and DRB1*11 were associated with strong responses.

⁵

A Japanese study found that even the specific vaccine product mattered: two different HLA haplotypes showed different response rates depending on which brand of hepatitis B vaccine was used, suggesting that the way each vaccine formulation presents the antigen interacts with a person’s genetic makeup.

⁵

The practical takeaway is that if you are a true non-responder and have no obvious health condition explaining it, the cause is likely baked into your DNA. You did nothing wrong. Your immune system just has a harder time recognizing this particular antigen.

Age, Sex, and the Numbers That Shift the Odds

Even without unfavorable genetics, age and sex can tip the balance. A meta-analysis pooling data from multiple studies found that adults over 40 had roughly 1.9 times the non-response rate of younger adults, and men were about 1.4 times more likely to fail than women.

⁶

The sex difference has been examined closely in healthcare workers, a group that routinely gets tested after vaccination. In one large cohort, about 14.5 percent of male healthcare workers had antibody levels below the protective cutoff compared to 8 percent of females, and women maintained roughly 26 to 38 percent higher antibody concentrations than men over time.

⁷

That same study also found that people vaccinated after their first birthday developed stronger responses than those vaccinated in early infancy, which fits with the broader pattern of an immature infant immune system sometimes producing a weaker initial response.

Part of the sex gap appears linked to hormonal differences affecting immune function. Research found that the disparity was more pronounced in people vaccinated at older ages, when hormonal differences between males and females are greatest, than in those vaccinated as young children.

⁶

Obesity, Smoking, and Other Lifestyle Factors

Carrying excess body weight is one of the most consistent non-genetic predictors of vaccine failure. A meta-analysis found that obesity was significantly associated with non-response, and the risk climbed with increasing BMI.

⁸

The mechanisms behind this include chronic low-grade inflammation that alters how immune cells function and impaired T-cell responses. Among people with obesity, those who also had fatty liver disease showed particularly weak vaccine-specific immune responses.

⁹

Smoking and heavy alcohol use also reduce the odds of a good response.

¹⁰

One interesting nuance is that the effect of these lifestyle factors depends partly on where the shot is given, a point covered in the section below on injection site. In studies comparing arm and buttock injections, smoking and higher body fat predicted lower response rates only in the group that received buttock injections, not in those injected in the arm.

¹¹

Where the Needle Goes Matters More Than You Would Think

Before the mid-1980s, hepatitis B vaccine was commonly given as a buttock injection. Response rates were dismal. A study of employees who received all three doses in the buttock found that only 56 percent developed protective antibodies, far below the 90-plus percent rate expected from arm injection.

¹²

A direct comparison showed seroconversion rates of 93 percent with arm injection versus 72 percent with buttock injection, and the antibody levels achieved were dramatically different: geometric mean titers were over 17 times higher in the arm-injected group.

¹¹

The problem is straightforward: the gluteal area has a thick layer of fat, and injecting vaccine into fat rather than muscle significantly reduces the immune response. Guidelines were updated in 1985 to specify the deltoid muscle in the upper arm as the correct site, but if you received your vaccine series before that change, or if an injection was inadvertently delivered too superficially, the site of administration could explain your low antibody result.

Chronic Kidney Disease and Other Medical Conditions

People with chronic kidney disease are among the most well-studied groups for hepatitis B vaccine failure. Kidney disease impairs multiple arms of the immune system, and the further along the disease has progressed, the worse the vaccine works. In patients on hemodialysis, response rates to standard vaccination range from just 10 to 50 percent.

¹³

Vaccination earlier in the course of kidney disease, when kidney function is still relatively preserved, is far more effective.

¹⁴

HIV infection similarly blunts vaccine responses, which is why newer vaccine formulations have been studied specifically in people living with HIV. Celiac disease is another condition linked to poor hepatitis B vaccine response. In one study, 58 percent of pediatric celiac patients failed to reach protective antibody levels.

¹⁵

The association between celiac disease and vaccine non-response is thought to involve shared HLA genetic variants (since celiac disease itself is HLA-linked), and there is evidence that adherence to a gluten-free diet may improve the immune response to revaccination in celiac children.

¹⁶

Any condition that suppresses or distorts immune function, including organ transplantation, immunosuppressive medications, and diabetes, can reduce vaccine effectiveness, though the degree varies widely by condition and individual.

The Cold Chain Problem Nobody Talks About

Hepatitis B vaccine must be stored refrigerated and must never be frozen. The aluminum adjuvant in the vaccine, which helps stimulate the immune response, undergoes irreversible chemical changes when exposed to freezing temperatures. A laboratory study showed that freeze-thaw damage to the adjuvant alone, even without any damage to the antigen itself, was enough to reduce vaccine potency.

¹⁷

In well-resourced healthcare settings, cold chain failures are uncommon but not impossible. In settings with less reliable refrigeration, the problem is more significant. You would have no way of knowing whether the vaccine you received had been compromised by a cold chain break, but it is one more factor that can explain unexpected non-response in an otherwise healthy person.

What To Do If You Are a Non-Responder

The standard approach for someone who does not respond to the initial three-dose series is to repeat the series. This works more often than people expect. In one study, hospital staff who received additional vaccine doses after failing the initial three-shot series achieved protective antibody levels in about 61 percent of cases after one or two extra doses.

¹⁸

A post-marketing study with a longer follow-up found even better results: when non-responders and low-responders stuck with a revaccination schedule through up to three booster doses, all of them eventually reached protective antibody levels.

¹⁹

For people who fail revaccination with standard vaccines, several alternative strategies exist:

Adjuvanted vaccines: Heplisav-B uses a different adjuvant that produces a stronger immune response. In a study of people living with HIV who had previously failed standard vaccines, about 87 percent became seropositive after completing a Heplisav-B series.

²⁰

Intradermal injection: Delivering smaller doses of vaccine into the skin rather than muscle activates a different population of immune cells. Studies have shown that about 70 percent of people who failed six previous intramuscular vaccine doses developed protective antibodies after three intradermal vaccinations.

²¹

Higher-dose formulations: Some protocols use double-dose vaccine or vaccines designed specifically for immunocompromised patients, such as Fendrix, which uses a different adjuvant system.

²²

These alternative approaches can be combined, and clinical experience suggests that persistence pays off. The key is not to assume that initial non-response means permanent non-response.

Occult Hepatitis B Infection

A less commonly discussed reason for apparent vaccine failure is that some people may have already been infected with hepatitis B before or after vaccination without knowing it. Occult hepatitis B infection refers to cases where the standard screening test (HBsAg) is negative but viral DNA is still detectable in the blood at low levels. A study of fully vaccinated, HBsAg-negative healthcare workers in Ethiopia found that about 10 percent had detectable hepatitis B DNA, confirming occult infection. Most of these cases involved very low viral loads, but one in five had higher levels.

²³

Occult infection matters in this context for two reasons. First, it means that a person who appears to have “failed” the vaccine may actually have encountered the virus and developed an atypical infection pattern. Second, it highlights that vaccine-induced immunity, while excellent, is not absolute, particularly in high-exposure settings. Standard antibody testing alone cannot detect occult infection; that requires DNA testing, which is not part of routine post-vaccination screening.

The Emerging Role of Gut Bacteria

An intriguing newer area of research looks at whether the composition of your gut microbiome influences how well you respond to vaccines. A review of the evidence found associations between specific gut bacteria and vaccine immunogenicity across several vaccines, including hepatitis B.

²⁴

A study in Ugandan fishing communities found that higher gut microbial diversity was associated with better hepatitis B vaccine responses, while older age was linked to weaker responses.

²⁵

This research is still in its early stages, and nobody is suggesting that taking a probiotic will fix vaccine non-response. But it points to a broader picture in which the immune system’s ability to respond to any vaccine depends on a web of factors, from your genes to your gut flora to your metabolic health, that we are only beginning to map. For the individual sitting in a doctor’s office puzzling over a negative antibody test, the practical steps remain the same: revaccinate, consider an adjuvanted or intradermal approach if standard doses fail, and remember that a low antibody number years after vaccination is not the same thing as an immune system that never learned to fight the virus.